All News

8 September 2010

New Octapharma 10% High Purity Immunoglobulin Enters Phase II/III Study in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Antibodies

7 September 2010

TenX Biopharma Reinitiates Enrollment in Pivotal Phase III, CTCL TrialAntibodies

2 September 2010

Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Agensys, an Affiliate of AstellasAntibodies

2 September 2010

MorphoSys Initiates Program Against Drug-Resistant MRSA InfectionsAntibodies

1 September 2010

Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal CancerAntibodies

31 August 2010

BTG plc (BGC.L) Signs $16.6 Mln Deal To Sell Nycomed’s Antivenom DrugsAntibodies

30 August 2010

MedImmune receives complete response letter on motavizumabAntibodies

27 August 2010

Genentech Receives Refuse to File Letter from FDA for T-DM1Antibodies

19 August 2010

Human Genome Sciences and GlaxoSmithKline Announce FDA Priority Review Designation for BENLYSTA (belimumab) as a Potential Treatment for Systemic Lupus ErythematosusAntibodies

18 August 2010

Ipilimumab Receives FDA Priority Review Designation for Adult Patients with Previously Treated Advanced MelanomaAntibodies

16 August 2010

Morphotek, Inc. Announces Initiation of a Phase I Study for MORAb-028, an IgM-Type Monoclonal Antibody, in Patients with Advanced MelanomaAntibodies

13 August 2010

NICE concludes omalizumab is not an effective use of NHS resources for children under 12Antibodies

11 August 2010

Biotest AG: Development of BT-062 makes further progress with start of a new clinical trialAntibodies

11 August 2010

Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer TrialAntibodies

10 August 2010

Immunomodulatory antibody BT-061 shows competitive efficacy in the indication Rheumatoid ArthritisAntibodies

10 August 2010

Scancell Signs Antibody Licence Agreement with Cancer Research TechnologyAntibodies

10 August 2010

MabVax Therapeutics Receives $1.1 Million Phase 2 Small Business Technology Transfer Program Award From The National Cancer InstituteAntibodies

10 August 2010

Genmab Announces Top-Line Interim Results for Ofatumumab in Diffuse Large B-Cell LymphomaAntibodies

10 August 2010

Centocor Ortho Biotech Inc.: STELARA(R) Three-Year Efficacy and Safety Data Presented on Patients with Moderate to Severe Plaque PsoriasisAntibodies

9 August 2010

GSK and Genmab Announce Topline Results from the Concluded Pivotal Trial of Arzerra (Ofatumumab) in Fludarabine and Alemtuzumab Refractory Chronic Lymphocytic LeukemiaAntibodies

4 August 2010

ACTEMRA Humanized Anti-Human IL-6 Receptor Monoclonal AntibodyAntibodies

4 August 2010

Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for AnthraxAntibodies

4 August 2010

Glycotope Received Regulatory Approval for Glycooptimized and Fully Human Glycosylated Antibody CetuGEX and Enrolls First Patients in Clinical TrialAntibodies

4 August 2010

Clinical Phase I Results of GANYMED’s iMAB362 Antibody Demonstrate Excellent SafetyAntibodies

3 August 2010

Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with GenentechAntibodies

2 August 2010

MorphoSys Announces Clinical Milestone from Strategic AllianceAntibodies

29 July 2010

Anthera Initiates Expanded and Extended PEARL-SC Phase 2b Clinical Study in Lupus With A-623 – A Subcutaneous Dual Inhibitor of Membrane and Soluble B-Cell Activating Factor (BAFF or BLyS)Antibodies

28 July 2010

Astellas to Pay $295 Million to Extend License of Regeneron’s VelocImmune Antibody Technology through 2023Antibodies

26 July 2010

NovImmune Enters Exclusive Antibody Licensing Agreement with GenentechAntibodies

22 July 2010

Merrimack Pharmaceuticals and sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 and exemestane in Breast CancerAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Ranibizumab (Lucentis) Biosimilars Pipeline Review

FcRn Inhibitors Pipeline Review

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Report Package: Claudin 18.2-Targeted Immunotherapeutics

Ustekinumab (Stelara) Biosimilars Pipeline Review

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis